PPD to go public once again

PPD
Pharmaceutical Product Development went private in 2011. (PPD)

Major CRO player Pharmaceutical Product Development (PPD) is set to go back on the public markets after announcing its IPO plans.

The CRO went private all the way back in 2011 when it was bought by Carlyle Group and Hellman & Friedman in a $3.9 billion deal. Two years ago, it recapitalized, with the owners expanding the company’s ownership to include two new investors: a subsidiary of the Abu Dhabi Investment Authority and an affiliate of GIC, Singapore’s sovereign wealth fund.

This valued the company at around $9 billion.

Now, PPD says it “has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission relating to the proposed initial public offering of the parent company’s common stock.”

RELATED: PPD boosts U.S. bioanalytical lab with hundreds of new staffers, expanded facilities

Pricing and shares offering have not yet been shared, but the CRO said it “expects to use the proceeds of the offering for general corporate purposes, which may include the repayment of indebtedness.”

This is a reverse of rival Parexel, which had been public until 2017 when it was bought out for $5 billion and taken private.

Read more on

Suggested Articles

While most children exposed to the coronavirus suffer a mild infection, others develop a rare, severe reaction that attacks multiple organs at once.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.